On Oct 31, major Wall Street analysts update their ratings for $IDEX Corp (IEX.US)$, with price targets ranging from $230 to $248.
TD Cowen analyst Joseph C Giordano maintains with a buy rating, and maintains the target price at $230.
Baird analyst Michael Halloran maintains with a buy rating, and maintains the target price at $241.
Oppenheimer analyst Bryan Blair maintains with a buy rating, and maintains the target price at $238.
RBC Capital analyst Deane Dray maintains with a buy rating, and adjusts the target price from $236 to $248.
Furthermore, according to the comprehensive report, the opinions of $IDEX Corp (IEX.US)$'s main analysts recently are as follows:
Following Idex Corp.'s third-quarter earnings surpassing expectations, the company's modest 1% operating income beat and improved 2024 guidance forecasts were noted. However, the key factor contributing to the stock's 7% relief rally was the reported stabilization in the life sciences area within the Health & Science Technologies segment after a lengthy phase of destocking and underperformance.
The firm noted that Idex Corp.'s 3Q results were operationally aligned, with upside from FSDP counterbalancing downside in FMT. The company's 2024 guidance improved at the lower end, and the 4Q outlook aligns with consensus. Additionally, signs of stabilization are emerging, as indicated by daily order rates, demand commentary, and estimates, which is a positive development after a challenging time for the company.
Here are the latest investment ratings and price targets for $IDEX Corp (IEX.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間10月31日，多家華爾街大行更新了$IDEX Corp (IEX.US)$的評級，目標價介於230美元至248美元。
TD Cowen分析師Joseph C Giordano維持買入評級，維持目標價230美元。
貝雅分析師Michael Halloran維持買入評級，維持目標價241美元。
奧本海默控股分析師Bryan Blair維持買入評級，維持目標價238美元。
加皇資本市場分析師Deane Dray維持買入評級，並將目標價從236美元上調至248美元。
此外，綜合報道，$IDEX Corp (IEX.US)$近期主要分析師觀點如下：
在Idex Corp.第三季度業績超出預期後，公司的適度的1%營業收入增長和改善的2024年指引預測受到關注。然而，導致股票上漲7%的主要因素是在長期的去庫存和表現不佳階段後，衛生科技部門的生命科學領域出現了穩定的報告。
公司指出，Idex Corp.的第三季度業績在運營上達到一致，FSDP的增長抵消了FMt的下降。公司的2024年指引在底部改善，第四季度展望與共識一致。此外，跡象顯示正在出現穩定跡象，如日常訂單率、需求評論和估計，這是公司經歷了具有挑戰性的時期後的積極發展。
以下爲今日4位分析師對$IDEX Corp (IEX.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
